Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
-
ORGANIZATION TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
-
BUSINESS LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
-
ORGANIZATION JPMA’s New Code of Practice to Take Effect in April; Transparency in Relations with Wholesalers to Be One Focus
February 22, 2013
-
ORGANIZATION Osaka-Based NPO to Take on Outsourcing of GMP Compliance Audit on Drug Substance Makers
February 21, 2013
-
BUSINESS DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
-
BUSINESS Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
-
BUSINESS Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
-
BUSINESS AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
-
BUSINESS Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
-
ORGANIZATION RAD-AR Council to Set Guidelines for Information Provisioning on Ethical Drugs
February 12, 2013
-
ORGANIZATION JMA Exec. Mikami Wants a Hold on Info Disclosures Based on Transparency Guidelines
February 8, 2013
-
BUSINESS Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
-
REGULATORY NIHS to Accelerate Medical Innovation Research
February 7, 2013
-
BUSINESS Novartis Jettisons Key Evidence from Diovan Promotion
February 6, 2013
-
BUSINESS Nesp, Mircera Jostling for Market Shares of Pre-Dialysis CKD Patients
February 5, 2013
-
BUSINESS Aricept Fails to Meet Minimum Sales Target in Japan: Eisai
February 4, 2013
-
BUSINESS Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications
February 4, 2013
-
BUSINESS Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium
February 1, 2013
-
REGULATORY CRO Association to Compile Guidelines for Third-Party Outsourcing after GCP Revision
February 1, 2013
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…